Glycosidase inhibitors: A patent review (2008-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 8, 2014, Pages 857-874

  Brás, Natércia F ^a   Cerqueira, Nuno M F S A ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Carbasugars; Catalytic mechanism; Cystic fibrosis; Diabetes; Disaccharides; Gaucher's disease; Glucosidases; Glycosidases; Iminosugars; Inhibitors; Non glycosidic inhibitors; Thiosugars

Indexed keywords

CARBASUGAR; DISACCHARIDE; GLYCOSIDASE INHIBITOR; IMINOSUGAR; OISACCHARIDE DERIVATIVE INHIBITOR; THIOSUGAR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLYCOSIDASE;

CHRONIC DISEASE; DRUG BIOAVAILABILITY; DRUG INDUSTRY; HUMAN; PANDEMIC; PATENT; REVIEW; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; DRUG DESIGN; ENZYMOLOGY; METABOLIC DISEASES; VIRUS DISEASES;

BIOLOGICAL AVAILABILITY; DRUG DESIGN; ENZYME INHIBITORS; GLYCOSIDE HYDROLASES; HUMANS; METABOLIC DISEASES; PATENTS AS TOPIC; VIRUS DISEASES;

EID: 84904688162     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.916280     Document Type: Review

References (136)

1. Wolfenden R, Lu XD, Young G. Spontaneous hydrolysis of glycosides. J Am Chem Soc 1998;120(27):6814-15
2. Cantarel BL, Coutinho PM, Rancurel C, et al. The carbohydrate-active enzymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res 2009;37:D233-D38
3. Bras NF, Cerqueira NMFSA, Fernandes PA, Ramos MJ. Carbohydrate-binding modules from family 11: understanding the binding mode of polysaccharides. Int J Quantum Chem 2008;108(11):2030-40
4. Viegas A, Bras NF, Cerqueira NMFSA, et al. Molecular determinants of ligand specificity in family 11 carbohydrate binding modules-an NMR, X-ray crystallography and computational chemistry approach. Febs J 2008;275(10):2524-35
5. Henrissat B, Davies G. Structural and sequence-based classification of glycoside hydrolases. Curr Opin Struc Biol 1997;7(5):637-44
6. Desmet T, Soetaert W. Enzymatic glycosyl transfer: mechanisms and applications. Biocatal Biotransfor 2011;29(1):1-18
7. Vocadlo DJ, Davies GJ. Mechanistic insights into glycosidase chemistry. Curr Opin Chem Biol 2008;12(5):539-55
8. Passos O, Fernandes PA, Ramos MJ. QM/MM study of the catalytic mechanism of GalNAc removal from GM2 ganglioside catalyzed by human beta-hexosaminidaseA. J Phys Chem B 2011;115(49):14751-9
9. Zechel DL, Withers SG. Glycosidase mechanisms: anatomy of a finely tuned catalyst. Accounts Chem Res 2000;33(1):11-18
10. Withers SG, Aebersold R. Approaches to labeling and identification of active-site residues in glycosidases. Protein Sci 1995;4(3):361-72
11. Bras NF, Fernandes PA, Ramos MJ. QM/MM studies on the beta-galactosidase catalytic mechanism: hydrolysis and transglycosylation reactions. J Chem Theory Comput 2010;6(2):421-33
12. Bras NF, Moura-Tamames SA, Fernandes PA, Ramos MJ. Mechanistic studies on the formation of glycosidase-substrate and glycosidase-inhibitor covalent intermediates. J Comput Chem 2008;29(15):2565-74
13. Bras NF, Ramos MJ, Fernandes PA. DFT studies on the beta-glycosidase catalytic mechanism: the deglycosylation step. J Mol Struc Theochem 2010;946(1-3):125-33
14. Bras NF, Fernandes PA, Ramos MJ. Docking and molecular dynamics studies on the stereoselectivity in the enzymatic synthesis of carbohydrates. Theor Chem Acc 2009;122(5-6):283-96
15. Petersen L, Ardevol A, Rovira C, Reilly PJ. Molecular mechanism of the glycosylation step catalyzed by golgi alpha-mannosidase II: a QM/MM metadynamics investigation. J Am Chem Soc 2010;132(24):8291-300
16. Vallee F, Karaveg K, Herscovics A, et al. Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1, 2-mannosidases. J Biol Chem 2000;275(52):41287-98
17. Vasella A, Davies GJ, Bohm M. Glycosidase mechanisms. Curr Opin Chem Biol 2002;6(5):619-29
18. Lai ECK, Morris SA, Street IP, Withers SG. Substituted glycals as probes of glycosidase mechanisms. Bioorgan Med Chem 1996;4(11):1929-37
19. Namchuk M, Braun C, McCarter JD, Withers SG. Fluorinated sugars as probes of glycosidase mechanisms. ACS Symp Ser 1996;639:279-93
20. Davies GJ, Planas A, Rovira C. Conformational analyses of the reaction coordinate of glycosidases. Acc Chem Res 2012;45(2):308-16
21. Gloster TM, Turkenburg JP, Potts JR, et al. Divergence of catalytic mechanism within a glycosidase family provides insight into evolution of carbohydrate metabolism by human gut flora. Chem Biol 2008;15(10):1058-67
22. Babu YS, Chand P, Kotian PL. Influenza neuraminidase inhibitors as antiviral agents. Annu Rep Med Chem 2006;41:287-97
23. Mehta A, Zitzmann N, Rudd PM, et al. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. Febs Lett 1998;430(1-2):17-22
24. Karpas A, Fleet GWJ, Dwek RA, et al. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA 1988;85(23):9229-33
25. Kawamura A, Nash R, Roach AG, inventors. Treatment of protein folding disorders patent. WO2009066069A1; 2009
26. Aerts JMFG, Boot RG; inventors. Treatment of cystic fibrosis patent. US20090186862A1; 2009
27. Fleet GWJ; inventor. Pyrrolidine iminosugars used in the treatment of cystic fibrosis patent. WO2011086347A1;2011
28. Kaushal S, Noorwez SM; inventors. Small compounds that correct protein misfolding and uses thereof patent. US20100004156A1; 2010
29. Becq F, Norez C; inventors. Use of glucosidase inhibitors for therapy of mucovisidosis patent. US8242136B2; 2012
30. Asano N. Sugar-mimicking glycosidase inhibitors: bioactivity and application. Cell Mol Life Sci 2009;66(9):1479-92
31. Asano N, Nash RJ, Molyneux RJ, Fleet GWJ. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron Asymmetr 2000;11(8):1645-80
32. Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005;15(10):R43-52
33. Cerqueira NMFSA, Fernandes PA, Ramos MJ. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat AntiCancer Drug Discov 2007;2(1):11-29
34. Asano N. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 2003;13(10):93R-104R
35. Ugalde RA, Staneloni RJ, Leloir LF. Microsomal glucosidases of rat-liver-partial-purification and inhibition by disaccharides. Eur J Biochem 1980;113(1):97-103
36. Sato A, Aso K. Kojibiose (2-O-alpha-D-glucopyranosyl-D-glucose)-Isolation and structure-Isolation from hydrol. Nature 1957;180(4593):984-5
37. Wolfrom ML, Thompson A. Degradation of amylopectin to nigerose. J Am Chem Soc 1955;77(23):6403-3
38. Postema MHD, Piper JL, Liu L, et al. Synthesis and partial biological evaluation of a small library of differentially-linked beta-C-disaccharides. J Organ Chem 2003;68(12):4748-54
39. Horne G, Wilson FX, Tinsley J, et al. Iminosugars past, present and future: medicines for tomorrow. Drug Discov Today 2011;16(3-4):107-18
40. Nash RJ, Kato A, Yu CY, Fleet GWJ. Iminosugars as therapeutic agents: recent advances and promising trends. Future Med Chem 2011;3(12):1513-21
41. Lahiri R, Ansari AA, Vankar YD. Recent developments in design and synthesis of bicyclic azasugars, carbasugars and related molecules as glycosidase inhibitors. Chem Soc Rev 2013;42(12):5102-18
42. D'Alonzo D, Guaragna A, Palumbo G. Glycomimetics at the mirror: medicinal chemistry of L-iminosugars. Curr Med Chem 2009;16(4):473-505
43. Nash RJ, Fellows LE, Dring JV, et al. Isolation from alexa-leiopetala and X-ray crystal-structure of alexine, (1R, 2R, 3R, 7S, 8S)-3-hydroxymethyl-1, 2, 7-trihydroxypyrrolizidine (2R, 3R, 4R, 5S, 6S)-2-hydroxymethyl-1-azabicyclo 3.3.0 octan-3, 4, 6-triol, a unique pyrrolizidine alkaloid. Tetrahedron Lett 1988;29(20):2487-90
44. Hussain RA, Kinghorn AD, Molyneux RJ. Alkaloids of papilionoideae. 4. Alkaloids of rothia-trifoliata and rothia-hirsuta. J Nat Prod 1988;51(4):809-11
45. Tepfer D, Goldmann A, Pamboukdjian N, et al. A plasmid of Rhizobium-meliloti-41 encodes catabolism of compounds from root exudate of calystegium-sepium. J Bacteriol 1988;170(3):1153-61
46. Nash RJ, Rothschild M, Porter EA, et al. Calystegines in solanum and datura species and the deaths-head hawk-moth (Acherontia-atropus). Phytochemistry 1993;34(5):1281-3
47. Asano N, Yamauchi T, Kagamifuchi K, et al. Iminosugar-producing Thai medicinal plants. J Nat Prod 2005;68(8):1238-42
48. Asano N. Water soluble nortropane alkaloids in crude drugs, edible fruits and vegetables: biological activities and therapeutic applications. Mech Ageing Dev 2000;116(2-3):155-6
49. Kite GC, Horn JM, Romeo JT, et al. Alpha-homonojirimycin and 2, 5-dihydroxymethyl-3, 4-dihydroxy-pyrrolidine-Alkaloidal glycosidase inhibitors in the moth urania-fulgens. Phytochemistry 1990;29(1):103-5
50. Watson AA, Nash RJ, Wormald MR, et al. Glycosidase-inhibiting pyrrolidine alkaloids from Hyacinthoides non-scripta. Phytochemistry 1997;46(2):255-9
51. Winchester BG. Iminosugars: from botanical curiosities to licensed drugs. Tetrahedron Asymmetry 2009;20(6-8):645-51
52. Molyneux RJ, Benson M, Wong RY, et al. Australine, a novel pyrrolizidine alkaloid glucosidase inhibitor from Castanospermum-australe. J Nat Prod 1988;51(6):1198-206
53. Nash RJ; inventors. Myrtaceous honey and the use thereof as immunomodulator patent. WO2006067419A3, WO2006067419A3; 2006
54. Fleet GWJ, Storer R; inventors. Novel iminosugar therapeutics patent. WO2011095772A3; 2011
55. Steiner A, Stuetz A, Wrodnigg T; inventors. Iminosugar glycoconjugates patent. WO2008034575A1; 2008
56. James NR; inventors. Use of imino sugars in immunotherapy patent. WO2008009894A2; 2008
57. Hiroyoshi I; inventors. Glucosidase inhibitor patent. WO2008090999A1; 2008
58. Xie C, Zou Y; inventors. Extract of traditional Chinese medicine having alpha-glucosidase inhibitor activity and its application patent. WO2011032502A1; 2008
59. Bilgic M; inventor. Synergic combination comprising anti-diabetic agent patent. WO2013095316A1; 2013
60. Lean TN, Chun-Han S, Min-Nan L; inventors. Alpha-glucosidase inhibitor patent. US20130165679A1; 2013
61. Benito JM, Fernandez JMG, Mellet CO. Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin Ther Patents 2011;21(6):885-903
62. Wilson FX, Nash RJ, Horne G, inventors. Treatment of lysosomal storage disorders and other proteostatic diseases patent. WO2010015816A2; 2010
63. GARCIA JM, Ortiz MC, Garcia M, inventors. Compounds promoting the activity of mutant glycosidases patent. WO2010046517A1; 2010
64. Dwek AR, Nichita-Branza N, Stefana P, et al. inventors. Liposome treatment of viral infections patent. US20080138351A1; 2008
65. Block TM, Chang J, Xu X; inventors. Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity patent. WO2010027996A1; 2010
66. Inouye S, Tsuruoka T, Niida T. Structure of nojirimycin, a piperidinose sugar antibiotic. J Antibiot 1966;19(6):288-92
67. Koyama M, Sakamura S. Structure of a new piperidine derivative from Buckwheat seeds-Fagopyrum-esculentum moench. Agric Biol Chem 1974;38(5):1111-12
68. Yagi M, Kouno T, Aoyagi Y, Murai H. Structure of moranoline, a piperidine alkaloid from Morus species. J Agric Chem Soc Jpn 1976;50(11):571-2
69. Kato A, Kato N, Kano E, et al. Biological properties of D-and L-1-deoxyazasugars. J Med Chem 2005;48(6):2036-44
70. Gloster TM, Davies GJ. Glycosidase inhibition: assessing mimicry of the transition state. Organ Biomol Chem 2010;8(2):305-20
71. Jespersen TM, Bols M, Sierks MR, Skrydstrup T. Synthesis of isofagomine, a novel glycosidase inhibitor. Tetrahedron 1994;50(47):13449-60
72. Jespersen TM, Dong WL, Sierks MR, et al. Isofagomine, a potent, new glycosidase inhibitor. Angew Chemie Int Ed Engl 1994;33(17):1778-9
73. Erwin MK, Wilhelm SF, Erwin W, Piepenbrink UB; inventors. Isocyanate-modified polyesters reacted with glycols patent. US2729618A; 1956
74. Sawkar AR, Cheng WC, Beutler E, et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 2002;99(24):15428-33
75. Butters TD, Dwek RA, Neises GR, Platt FM; inventors. Method of inhibiting glycolipid synthesis patent. US5525616A; 1996
76. Rosner H; inventor. Use of drug miglitol (Glyset) for treatment of obesity to prevent weight gain for losing weight and for weight control patent. US6683098B1; 2004
77. Sorbera LA, Castaner J, Bayes M. Miglustat. Treatment of Gaucher's disease, ceramide glucosyltransferase inhibitor, alpha-glucosidase inhibitor. Drugs Future 2003;28(3):229-36
78. Du Y, Xu X, Ye H, inventors. Novel alkylated imino sugars exhibiting glucosidase inhibition and their method of use patent. WO2013148791A1; 2013
79. Ramstedt U, Klose B, Zitzmann N, inventors. Iminosugars and methods of treating filoviral diseases patent. WO2011028779A1; 2011
80. Ramstedt U, Klose B, Zitzmann N, inventors. Iminosugars and methods of treating bunyaviral and togaviral diseases patent. WO2010144759A1; 2010
81. Ramstedt U, Klose B, Zitzmann N, inventors. Iminosugars and methods of treating arenaviral infections patent. WO2010099064A1; 2010
82. Wilson FX, Nash RJ, Horne G, inventors. Compounds for the treatment of flaviviral infections patent. WO2010015815A2; 2010
83. Blatt LM, Tan H, Seiwert SD; inventors. Use of alpha-glucosidase inhibitors to treat alphavirus infections patent. US20110177026A1; 2011
84. Zarate YA, Hopkin RJ. Lysosomal storage disease 3-Fabry's disease. Lancet 2008;372(9647):1427-35
85. Sugawara K, Tajima Y, Kawashima I, et al. Molecular interaction of imino sugars with human alpha-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol Genet Metab 2009;96(4):233-8
86. Colegate SM, Dorling PR, Huxtable CR. Spectroscopic investigation of swainsonine-alpha-mannosidase inhibitor isolated from Swainsona-canescens. Aust J Chem 1979;32(10):2257-64
87. Hohenschutz LD, Bell EA, Jewess PJ, et al. Castanospermine, a 1, 6, 7, 8-tetrahydroxyoctahydroindolizine alkaloid, from seeds of Castanospermum- australe. Phytochemistry 1981;20(4):811-14
88. Elbein AD, Solf R, Dorling PR, Vosbeck K. Swainsonine-an inhibitor of glycoprotein processing. Proc Natl Acad Sci USA 1981;78(12):7393-7
89. Cerqueira NMFSA, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 2005;12(11):1283-94
90. Sorbera LA, Castaner J, Garcia-Capdevila L. Celgosivir-alpha-glucosidase inhibitor anti-hepatitis C virus drug. Drugs Future 2005;30(6):545-52
91. Choukhi A, Ung S, Wychowski C, Dubuisson J. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J Virol 1998;72(5):3851-8
92. Hu XG, Bartholomew B, Nash RJ, et al. Synthesis and glycosidase inhibition of the enantiomer of (-)-steviamine, the first example of a new class of indolizidine alkaloid. Org Lett 2010;12(11):2562-5
93. Goldmann A, Message B, Tepfer D, et al. Biological activities of the nortropane alkaloid, calystegine B-2, and analogs: structure-function relationships. J Nat Prod 1996;59(12):1137-42
94. Mellor HR, Neville DCA, Harvey DJ, et al. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. Biochem J 2004;381:861-6
95. Witczak ZJ, Culhane JM. Thiosugars: new perspectives regarding availability and potential biochemical and medicinal applications. Appl Microbiol Biotechnol 2005;69(3):237-44
96. Pinto BM, Mohan S, Nasi R, inventors. Salacinol and ponkoranol homologues, derivatives thereof, and methods of synthesizing same patent. WO066653; 2011
97. Pinto BM, Kumarasamy J, Nasi R, Mohan S; inventors. Methods for synthesizing kotalanol and stereoisomers and analogues thereof, and novel compounds produced thereby patent. WO2009117829A1; 2009
98. Yoshikawa M, Morikawa T, Matsuda H, et al. Absolute stereostructure of potent alpha-glucosidase inhibitor, salacinol, with unique thiosugar sulfonium sulfate inner salt structure from Salacia reticulata. Bioorgan Med Chem 2002;10(5):1547-54
99. Yoshikawa M, Murakami T, Yashiro K, Matsuda H. Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata. Chem Pharm Bull 1998;46(8):1339-40
100. Yoshikawa M, Murakami T, Shimada H, et al. Salacinol, potent antidiabetic principle with unique thiosugar sulfonium sulfate structure from the ayurvedic traditional medicine Salacia reticulata in Sri Lanka and India. Tetrahedron Lett 1997;38(48):8367-70
101. Kremer L, Douglas JD, Baulard AR, et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000;275(22):16857-64
102. Gloster TM, Zandberg WF, Heinonen JE, et al. Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat Chem Biol 2011;7(3):174-81
103. Kajimoto T, Liu KKC, Pederson RL, et al. Enzyme-catalyzed aldol condensation for asymmetric-synthesis of azasugars-synthesis, evaluation, and modeling of glycosidase inhibitors. J Am Chem Soc 1991;113(16):6187-96
104. Ding YL, Hindsgaul O. Syntheses of 1-deoxy-3-S-(1-thio-alpha-D- glucopyranosyl)-mannojirimycin and 1-deoxy-3-O-(5-thio-alpha-D-glucopyranosyl)- mannojirimycin as potential inhibitors of endo-alpha-D-mannosidase. Bioorg Med Chem Lett 1998;8(10):1215-20
105. Molyneux RJ, James LF. Loco intoxication-indolizidine alkaloids of spotted locoweed (Astragalus-lentiginosus). Science 1982;216(4542):190-1
106. Nakamura S, Takahira K, Tanabe G, et al. Docking and SAR studies of salacinol derivatives as alpha-glucosidase inhibitors. Bioorg Med Chem Lett 2010;20(15):4420-3
107. McCasland GE, Naumann MO, Durham LJ. Alicyclic carbohydrates. 30. Synthesis of remaining cyclohexanetriols. Nuclear Magnetic Resonance Studies on 9 Isomers. J Org Chem 1966;31(10):3079-89
108. McCasland GE, Furuta S, Durham LJ. Alicyclic carbohydrates. 29. synthesis of a pseudo-hexose (2, 3, 4, 5-tetrahydroxycyclohexanemethanol). J Org Chem 1966;31(5):1516-21
109. Nobuji Y, Noriko C, Takashi M, inventors. Novel bioactive substance MK7607 and its production. Japan patent. JP06306000; 1994
110. Ogawa S, Kanto M. Design and synthesis of 5a-carbaglycopyranosylamime glycosidase inhibitors. Curr Top Med Chem 2009;9(1):58-75
111. Lillelund VH, Jensen HH, Liang XF, Bols M. Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev 2002;102(2):515-53
112. Mahmud T, Lee S, Floss HG. The biosynthesis of acarbose and validamycin. Chem Rec 2001;1(4):300-10
113. Rauenbusch E; inventor. Highly pure acarbose patent. US4904769A; 1990
114. Bilgic M; inventor. Micronized acarbose patent. WO2013115738A1; 2013
115. Namiki S, Kangouri K, Nagate T, et al. Studies on the alpha-glucoside hydrolase inhibitor, adiposin. 1. Isolation and physicochemical properties. J Antibiot 1982;35(9):1234-6
116. Sakairi N, Kuzuhara H. Synthesis of amylostatin (Xg), alpha-glucosidase inhibitor with basic pseudotrisaccharide structure. Tetrahedron Lett 1982;23(50):5327-30
117. Vertesy L, Fehlhaber HW, Schulz A. The trehalase inhibitor salbostatin, a novel metabolite from Streptomyces-albus, Atcc21838. Angew Chem Int Edit 1994;33(18):1844-6
118. Yokose K, Ogawa K, Sano T, et al. New alpha-amylase inhibitor, trestatins. 1. Isolation, characterization and biological-activities of trestatin-A, trestatin-B and trestatin-C. J Antibiot 1983;36(9):1157-65
119. Yang JT, Xu H, Zhang YR, et al. Nucleotidylation of unsaturated carbasugar in validamycin biosynthesis. Org Biomol Chem 2011;9(2):438-49
120. Horii S, Kawahara K, Kameda Y. Studies on validamycins, new antibiotics. 8. Isolation and characterization of validamycin-C, validamycin-D, validamycin-E and validamycin-F. J Antibiot 1972;25(1):48-53
121. Asano N, Yamaguchi T, Kameda Y, Matsui K. Effect of validamycins on glycohydrolases of Rhizoctonia-solani. J Antibiot 1987;40(4):526-32
122. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu (R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemoth 2005;55:5-21
123. Layne SP, Monto AS, Taubenberger JK. Pandemic influenza: an inconvenient mutation. Science 2009;323(5921):1560-1
124. Xuewei L, Jimei M; inventors. Method of forming oseltamivir and derivatives thereof patent. WO2009078813A1; 2009
125. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008;453(7199):1258-U61
126. Bardot S; inventor. Method for the manufacture of a pharmaceutical form of oseltamivir phosphate patent. WO2007080321A1; 2007
127. Bilgic M; inventor. A process for production of pharmaceutical (effervescent) composition comprising alpha-glucosidases inhibitor (e.g vogliobose and metformin) patent. WO2013115745; 2013
128. Ota N; inventor. Method for producing n-alkyl-beta-valienamine analogue patent. WO2011078302A1; 2011
129. Fridman M, Flescher E, Briner-Goldstein E, inventors. Aloe-emodin derivatives and use thereof for the treatment of cancer patent. WO2011089602A2; 2011
130. Sou S, Takahashi H, Yamasaki R, et al. Alpha-glucosidase inhibitors with a 4, 5, 6, 7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group. Chem Pharm Bull 2001;49(6):791-3
131. Sou S, Mayumi S, Takahashi H, et al. Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton. Bioorg Med Chem Lett 2000;10(10):1081-4
132. Niwa T, Doi U, Osawa T. Inhibitory activity of corn-derived bisamide compounds against alpha-glucosidase. J Agric Food Chem 2003;51(1):90-4
133. Takada K, Uehara T, Nakao Y, et al. Schulzeines A-C, new alpha-glucosidase inhibitors from the marine sponge Penares schulzei. J Am Chem Soc 2004;126(1):187-93
134. Nakao Y, Maki T, Matsunaga S, et al. Penasulfate A, a new alpha-glucosidase inhibitor from a marine sponge Penares sp. J Nat Prod 2004;67(8):1346-50
135. Gao H, Nishioka T, Kawabata J, Kasai T. Structure-activity relationships for alpha-glucosidase inhibition of baicalein, 5, 6, 7-trihydroxyflavone: the effect of A-ring substitution. Biosci Biotech Bioch 2004;68(2):369-75
136. Fukui Y, Iwashita T; inventors. Novel epigallocatechin gallate trimer, and a-glucosidase inhibitor comprising epigallocatechin gallate polymer patent. WO2010024396A1; 2010